United Biotech Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: United Biotech Private Limited Pharmaceutical Export Portfolio Dataset — 30 Products, $7.0M FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

United Biotech Private Limited — Pharmaceutical Exporter Profile (2026) | 30 Products, $7.0M Trade | TransData Nexus

United Biotech Private Limited

Indian Pharmaceutical Exporter · Advanced Oncology Specialist · $7.0M Total Trade · DGFT Verified

United Biotech Private Limited is an Indian pharmaceutical exporter with a total trade value of $7.0M across 30 products in 7 therapeutic categories. Based on 1,196 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Ertapenem ($1.3M), Doxorubicin ($508.7K), Voriconazole ($506.9K).

United Biotech Private Limited — Export Portfolio & Destination Treemap

United Biotech Private Limited pharmaceutical export portfolio — 30 products across 7 therapeutic categories. Source: Indian Customs (DGFT).

Who is United Biotech Private Limited? — Company Overview & Market Position

United Biotech Private Limited (UBPL) is a privately held pharmaceutical company established on January 31, 1997, in New Delhi, India. The company is registered under the Corporate Identification Number (CIN) U24239DL1997PTC084814. UBPL specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. As of December 20, 2025, the company reported an authorized capital of ₹5.00 crore and a paid-up capital of ₹4.54 crore.

The registered office is located at E-142, Saket, New Delhi, Delhi, 110017, India. UBPL employs approximately 831 professionals, reflecting its significant presence in the pharmaceutical manufacturing sector. The company's website, administration@unitedbiotechindia.com, serves as a point of contact for business inquiries.

What Does United Biotech Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Ertapenem$1.3M 2Doxorubicin

Product Portfolio — Top 30 by Export Value

United Biotech Private Limited exports 30 pharmaceutical products across 7 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Ertapenem	Advanced Antibiotics	$1.3M	29	1.2%	8
2	Doxorubicin	Oncology	$508.7K	111	0.8%	12
3	Voriconazole	Advanced Antifungals	$506.9K	29	1.6%	13
4	Cisplatin	Oncology	$489.4K	97	3.8%	8
5	Methylprednisolone	Corticosteroids	$429.2K	37	1.5%	11
6	Docetaxel	Oncology	$380.9K	75	1.0%	15
7	Ifosfamide	Advanced Oncology	$335.3K	68	13.7%	2
8	Amphotericin	Antifungals	$319.8K	27	0.4%	11
9	Thalidomide	Advanced Oncology	$307.7K	18	15.9%	2
10	Cytarabine	Advanced Oncology	$303.8K	116	2.8%	7
11	Gemcitabine	Oncology	$293.6K	57	0.6%	15
12	Nitroglycerin	Cardiovascular	$213.7K	12	2.2%	7
13	Pemetrexed	Advanced Oncology	$198.0K	41	0.7%	14
14	Dacarbazine	Advanced Oncology	$150.9K	63	8.7%	3
15	Bortezomib	Advanced Oncology	$143.6K	19	0.7%	12
16	Fludarabine	Advanced Oncology	$114.2K	25	4.0%	3
17	Cyclophosphamide	Oncology	$110.4K	75	0.6%	13
18	Vinorelbine	Advanced Oncology	$110.1K	23	3.2%	4
19	Anastrozole	Advanced Oncology	$100.7K	8	0.1%	11
20	Erlotinib	Advanced Oncology	$98.8K	7	3.7%	7
21	Vincristine	Oncology	$95.4K	32	4.7%	4
22	Epirubicin	Advanced Oncology	$94.6K	45	1.5%	9
23	Teicoplanin	Advanced Antibiotics	$91.2K	19	1.4%	8
24	Melphalan	Advanced Oncology	$70.8K	19	0.6%	9
25	Etoposide	Oncology	$65.9K	37	0.6%	13
26	Vinblastine	Oncology	$47.8K	29	6.4%	3
27	Gefitinib	Advanced Oncology	$45.6K	15	0.7%	7
28	Daunorubicin	Advanced Oncology	$42.4K	35	6.1%	4
29	Topotecan	Advanced Oncology	$18.9K	23	0.5%	4
30	Actinomycin	Advanced Oncology	$14.9K	5	0.5%	12

United Biotech Private Limited exports 30 pharmaceutical products across 7 therapeutic categories with a total export value of $7.0M. The top category is Advanced Oncology (30.8% of portfolio), followed by Oncology (28.5%), reflecting a diversified portfolio where the top 5 products account for only 46.0% of total value.

United Biotech Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

UBPL operates a state-of-the-art manufacturing facility in New Delhi, India. The plant is certified for WHO-cGMP and ISO 9001:2008, ensuring adherence to international quality standards. (about.me) This facility specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets.

3Key Leadership

The leadership team at UBPL comprises:

Rajiv Kumar: Whole-Time Director since January 31, 1997.
Sanjeev Kumar: Whole-Time Director since April 2, 2007.
Ashwani Kumar: Whole-Time Director since December 7, 2013.

These directors play pivotal roles in steering the company's strategic direction and operations.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does United Biotech Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

UBPL has made significant strides in regulated markets, obtaining approvals from various international regulatory bodies. The company has secured WHO prequalification for several of its products, facilitating access to markets in Africa, Latin America, and Southeast Asia. Additionally, UBPL holds EU GMP certificates, enabling it to export to European Union countries. The company's adherence to international standards underscores its commitment to quality and regulatory compliance.

2Emerging Markets

UBPL has strategically expanded its presence in emerging markets, including Africa, Latin America, and Southeast Asia. The WHO prequalification of its products has been instrumental in this expansion, allowing the company to meet the stringent requirements of these regions. This strategic focus has enhanced UBPL's global footprint and market diversification.

3Geographic Strategy

UBPL's geographic strategy emphasizes diversification, reducing reliance on any single market. The company's expansion into emerging markets, coupled with its presence in regulated markets, reflects a balanced approach to global market penetration. This strategy mitigates concentration risk and positions UBPL for sustained growth.

United Biotech Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

UBPL has registered its manufacturing facility with the U.S. Food and Drug Administration (FDA), allowing it to export pharmaceutical products to the United States. The company has filed multiple Abbreviated New Drug Applications (ANDAs) and Drug Master Files (DMFs), demonstrating its commitment to meeting FDA standards. UBPL's facilities have undergone FDA inspections, resulting in favorable outcomes, which attest to the company's adherence to stringent quality and regulatory requirements.

2WHO & EU GMP

UBPL's manufacturing facility holds WHO Good Manufacturing Practice (GMP) certification, ensuring compliance with international quality standards. The company also possesses EU GMP certificates, facilitating exports to European Union markets. These certifications reflect UBPL's dedication to maintaining high-quality manufacturing processes.

3CDSCO & Indian Regulatory

UBPL operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company holds the necessary manufacturing licenses and approvals from state drug controllers, ensuring compliance with Indian pharmaceutical regulations. UBPL also possesses export No Objection Certificates (NOCs), authorizing it to export pharmaceutical products to various international markets.

United Biotech Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

UBPL operates in a competitive landscape, with several pharmaceutical companies offering similar products in overlapping therapeutic categories. While specific market share data is not publicly disclosed, UBPL's focus on high-quality manufacturing and regulatory compliance positions it favorably in the market. The company's strategic expansion into emerging markets further enhances its competitive edge.

2Key Differentiators

UBPL's key differentiators include its state-of-the-art manufacturing facility certified for WHO-cGMP and ISO 9001:2008, a diverse product portfolio across multiple therapeutic categories, and a strong presence in both regulated and emerging markets. These factors collectively contribute to the company's competitive advantage in the pharmaceutical industry.

3Strategic Position

UBPL's current strategic direction focuses on expanding its presence in both regulated and emerging markets, leveraging its manufacturing capabilities and regulatory certifications. The company's future outlook includes further diversification of its product portfolio and geographic reach, aiming for sustained growth and leadership in the global pharmaceutical sector.

Buyer Due Diligence Brief — Evaluating United Biotech Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

UBPL has demonstrated a strong track record in pharmaceutical manufacturing, with consistent export volumes and adherence to international quality standards. The company's reliability is evidenced by its certifications and favorable regulatory inspections. UBPL's commitment to quality and compliance makes it a dependable supplier in the pharmaceutical industry.

2Certifications to Verify

Importers should verify the following certifications when considering UBPL as a supplier:

FDA Registration: Confirm the company's registration status with the U.S. Food and Drug Administration.
WHO GMP Certification: Ensure the manufacturing facility holds WHO Good Manufacturing Practice certification.
EU GMP Certification: Verify the presence of EU Good Manufacturing Practice certificates.
ISO 9001:2008 Certification: Check for ISO 9001:2008 certification, indicating adherence to quality management standards.

Frequently Asked Questions — United Biotech Private Limited

How many pharmaceutical products does United Biotech Private Limited export from India?

United Biotech Private Limited exports 30 pharmaceutical products across 7 therapeutic categories. The top exports are Ertapenem ($1.3M), Doxorubicin ($508.7K), Voriconazole ($506.9K), Cisplatin ($489.4K), Methylprednisolone ($429.2K). Total export value is $7.0M.

What is United Biotech Private Limited's total pharmaceutical export value?

United Biotech Private Limited's total pharmaceutical export value is $7.0M, based on 1,196 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does United Biotech Private Limited cover?

United Biotech Private Limited exports across 7 therapeutic categories. The largest are Advanced Oncology (30.8%, 16 products), Oncology (28.5%, 8 products), Advanced Antibiotics (19.6%, 2 products).

Get Full United Biotech Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.